Peer-reviewed veterinary case report
Using acute phase proteins to assess and manage canine leishmaniosis
By Ceron, J J et al.·Published in BMC veterinary research·2018·University of Murcia, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of acute phase proteins for the clinical assessment and management of canine leishmaniosis: general recommendations.
- Species:
- dog
Plain-English summary
A dog diagnosed with canine leishmaniosis (CanL) showed varying symptoms based on the severity of the disease. Dogs can be categorized into three groups: those with no symptoms and normal protein levels, those with abnormal protein levels but no symptoms, and those with both symptoms and abnormal protein levels. By measuring these proteins, veterinarians can better understand the dog's condition and tailor treatment accordingly. This approach helps in managing the disease more effectively, leading to improved outcomes for affected dogs.
People also search for: dog leishmaniosis symptoms · canine leishmaniosis treatment · dog protein levels test
Abstract
BACKGROUND: Dogs with canine leishmaniosis (CanL) due to Leishmania infantum can show a wide spectrum of clinical and clinicopathological findings at the time of diagnosis. The aim of this paper is to describe the possible application of acute phase proteins (APPs) for the characterization and management of this disease, based on previously published information on the utility of APPs in CanL and the experience of the authors in using APPs as analytes in the profiling of canine diseases. MAIN BODY: Dogs diagnosed with L. infantum infection by serology, polymerase chain reaction, cytological or histopathological identification, can be divided into three groups based on their clinical condition at physical examination and their APPs concentrations: Group 1: dogs with no clinical signs on physical examination and APPs in reference range; Group 2: dogs with changes in APPs but no clinical signs on physical examination; Group 3: dogs with clinical signs and changes in APPs. This report describes the main characteristics of each group as well as its association with the clinical classification schemes of CanL. CONCLUSION: APPs concentration can be a useful clinical tool to characterize and manage CanL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29925385/